Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xylose-derived lactam oxime is a synthetic small molecule compound derived from xylose, a pentose sugar commonly found in wood and plant materials[2][3]. Structurally, it features a piperidine (lactam) backbone with three hydroxyl groups at positions 3, 4, and 5, and an oxime group at position 2[3]. The compound belongs to the class of sugar oximes—molecules that have shown diverse biological activities including enzyme inhibition and potential as cholinesterase reactivators[5][6]. Sugar oximes are being explored for their ability to reactivate acetylcholinesterase (AChE) inhibited by organophosphates, suggesting possible use as antidotes for nerve agent or pesticide poisoning. Xylose-derived lactam oxime has also been studied as an experimental ligand for exoglucanase/xylanase from Cellulomonas fimi but does not have any approved medical indications or known clinical development beyond preclinical research[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xylose-derived lactam oxime.